IMRX Immuneering Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 1790340 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-6.4%
TTM EPS YoY48.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-33.5%
ROA-31.4%
ROIC (approx.)-105.3%
Asset turnover—
Leverage & solvency
Liabilities / assets7.6%
Debt / equity0.00x
Current ratio13.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-2.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $0 | $316,952 | $2.08M |
| Cost of revenue | — | — | $0 | $158,122 | $1.15M |
| Gross profit | — | — | $0 | $158,830 | $926,888 |
| R&D expense | $42.05M | $47.96M | $41.62M | $36.27M | $26.54M |
| SG&A expense | $17.30M | $16.08M | $16.76M | $15.61M | $8.27M |
| Operating income | -$59.38M | -$64.07M | -$58.41M | -$51.74M | -$33.89M |
| Pretax income | — | — | — | -$50.51M | -$33.84M |
| Income tax | $0 | — | — | — | -$307,485 |
| Net income | -$56.02M | -$61.04M | -$53.47M | -$50.51M | -$33.54M |
| EBITDA | -$59.05M | -$63.72M | -$58.09M | -$51.50M | -$33.84M |
| EPS (basic) | -1.27 | -2.04 | -1.88 | -1.91 | -2.46 |
| EPS (diluted) | -1.27 | -2.04 | -1.88 | -1.91 | -2.46 |
| Weighted avg. shares (diluted) | 44.01M | 29.98M | 28.42M | 26.39M | 13.61M |
| Balance sheet | |||||
| Cash & equivalents | $128.65M | $36.14M | $59.41M | $72.64M | $74.89M |
| Short-term investments | — | $0 | $26.26M | $32.89M | $74.31M |
| Receivables | — | — | $0 | $12,417 | $246,040 |
| Current assets | $176.25M | $39.59M | $89.08M | $108.75M | $152.33M |
| PP&E, net | $938,481 | $1.12M | $1.40M | $1.37M | $807,223 |
| Goodwill | $6.69M | $6.69M | $6.69M | $6.69M | $6.70M |
| Intangibles | $321,147 | $350,413 | $379,680 | $408,947 | $439,000 |
| Total assets | $231.99M | $52.71M | $102.58M | $122.37M | $166.70M |
| Current liabilities | $10.07M | $7.50M | $7.85M | $8.05M | $5.63M |
| Total liabilities | $13.50M | $11.33M | $12.01M | $12.52M | $10.72M |
| Shareholders' equity | $218.48M | $41.39M | $90.58M | $109.85M | $155.98M |
| Cash flow statement | |||||
| Operating cash flow | -$45.34M | -$55.00M | -$48.97M | -$44.10M | -$30.85M |
| Capital expenditure | $142,226 | $84,875 | $342,746 | $742,483 | $60,786 |
| Free cash flow | -$45.49M | -$55.08M | -$49.31M | -$44.84M | -$30.91M |
| Investing cash flow | -$88.74M | $26.43M | $7.30M | $41.83M | -$75.62M |
| Financing cash flow | $226.58M | $5.30M | $28.44M | $19,004 | $144.26M |
| Depreciation & amortization | $324,517 | $355,807 | $322,816 | $247,199 | $45,467 |
| Stock-based compensation | $6.31M | $6.50M | $5.73M | $4.06M | $1.80M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.